HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

Abstract
Immune-based therapies hold promise for the treatment of multiple myeloma (MM), but so far, immune checkpoint blockade targeting programmed cell death protein 1 has not proven effective as single agent in this disease. T-cell immunoglobulin and ITIM domains (TIGIT) is another immune checkpoint receptor known to negatively regulate T-cell functions. In this study, we investigated the therapeutic potential of TIGIT blockade to unleash immune responses against MM. We observed that, in both mice and humans, MM progression was associated with high levels of TIGIT expression on CD8+ T cells. TIGIT+ CD8+ T cells from MM patients exhibited a dysfunctional phenotype characterized by decreased proliferation and inability to produce cytokines in response to anti-CD3/CD28/CD2 or myeloma antigen stimulation. Moreover, when challenged with Vk*MYC mouse MM cells, TIGIT-deficient mice showed decreased serum monoclonal immunoglobulin protein levels associated with reduced tumor burden and prolonged survival, indicating that TIGIT limits antimyeloma immune responses. Importantly, blocking TIGIT using monoclonal antibodies increased the effector function of MM patient CD8+ T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.
AuthorsCamille Guillerey, Heidi Harjunpää, Nadège Carrié, Sahar Kassem, Tricia Teo, Kim Miles, Sophie Krumeich, Marianne Weulersse, Marine Cuisinier, Kimberley Stannard, Yuan Yu, Simone A Minnie, Geoffrey R Hill, William C Dougall, Hervé Avet-Loiseau, Michele W L Teng, Kyohei Nakamura, Ludovic Martinet, Mark J Smyth
JournalBlood (Blood) Vol. 132 Issue 16 Pg. 1689-1694 (10 18 2018) ISSN: 1528-0020 [Electronic] United States
PMID29986909 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2018 by The American Society of Hematology.
Chemical References
  • Antibodies, Monoclonal
  • Pdcd1 protein, mouse
  • Programmed Cell Death 1 Receptor
  • Receptors, Immunologic
  • T cell Ig and ITIM domain protein, mouse
  • TIGIT protein, human
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • CD8-Positive T-Lymphocytes (drug effects, immunology)
  • Cells, Cultured
  • Humans
  • Lymphocyte Activation (immunology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Multiple Myeloma (etiology, pathology, prevention & control)
  • Programmed Cell Death 1 Receptor (antagonists & inhibitors, immunology)
  • Receptors, Immunologic (antagonists & inhibitors, metabolism, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: